253 related articles for article (PubMed ID: 17100941)
1. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.
Burnett AL; Bivalacqua TJ; Champion HC; Musicki B
J Sex Med; 2006 Nov; 3(6):1077-1084. PubMed ID: 17100941
[TBL] [Abstract][Full Text] [Related]
2. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
Burnett AL; Bivalacqua TJ; Champion HC; Musicki B
Urology; 2006 May; 67(5):1043-8. PubMed ID: 16698365
[TBL] [Abstract][Full Text] [Related]
3. Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism.
Nardozza A; Cabrini MR
Rev Assoc Med Bras (1992); 2017 Aug; 63(8):689-692. PubMed ID: 28977106
[TBL] [Abstract][Full Text] [Related]
4. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy.
Furtado TP; Miranda EP; Deveci S; Jenkins L; Narus J; Nelson C; Mulhall JP
J Sex Med; 2023 Dec; 21(1):29-32. PubMed ID: 37973393
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
Broderick GA; Donatucci CF; Hatzichristou D; Torres LO; Valiquette L; Zhao Y; Loughney K; Sides GD; Ahuja S
J Sex Med; 2006 Jul; 3(4):668-675. PubMed ID: 16839323
[TBL] [Abstract][Full Text] [Related]
6. Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation.
Sopko NA; Matsui H; Hannan JL; Berkowitz D; Champion HC; Hsu LL; Musicki B; Burnett AL; Bivalacqua TJ
J Sex Med; 2015 Sep; 12(9):1878-85. PubMed ID: 26346631
[TBL] [Abstract][Full Text] [Related]
7. Glucose-6-phosphate dehydrogenase deficiency: an etiology for idiopathic priapism?
Burnett AL; Bivalacqua TJ
J Sex Med; 2008 Jan; 5(1):237-40. PubMed ID: 17971109
[TBL] [Abstract][Full Text] [Related]
8. New achievement and novel therapeutic applications of PDE5 inhibithors in older males.
Frajese GV; Pozzi F
J Endocrinol Invest; 2005; 28(3 Suppl):45-50. PubMed ID: 16042360
[TBL] [Abstract][Full Text] [Related]
9. Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health.
Burnett AL
J Androl; 2008; 29(1):3-14. PubMed ID: 17942972
[TBL] [Abstract][Full Text] [Related]
10. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy.
Broderick GA
J Sex Med; 2012 Jan; 9(1):88-103. PubMed ID: 21699659
[TBL] [Abstract][Full Text] [Related]
11. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction.
Fisher WA; Rosen RC; Eardley I; Niederberger C; Nadel A; Kaufman J; Sand M
J Sex Med; 2004 Sep; 1(2):150-60. PubMed ID: 16422969
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
Corbin JD
Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
[TBL] [Abstract][Full Text] [Related]
13. Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: a case report.
Tzortzis V; Mitrakas L; Gravas S; Mamoulakis C; Meissner A; Kyriakou D; Melekos MD
J Sex Med; 2009 Jul; 6(7):2068-71. PubMed ID: 19453903
[TBL] [Abstract][Full Text] [Related]
14. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
De Young L; Yu D; Freeman D; Brock GB
Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
[TBL] [Abstract][Full Text] [Related]
15. Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Jiang W; Sui Z; Macielag MJ; Walsh SP; Fiordeliso JJ; Lanter JC; Guan J; Qiu Y; Kraft P; Bhattacharjee S; Craig E; Haynes-Johnson D; John TM; Clancy J
J Med Chem; 2003 Jan; 46(3):441-4. PubMed ID: 12540243
[TBL] [Abstract][Full Text] [Related]
16. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities.
Xin ZC; Kim EK; Lin CS; Liu WJ; Tian L; Yuan YM; Fu J
Asian J Androl; 2003 Mar; 5(1):15-8. PubMed ID: 12646997
[TBL] [Abstract][Full Text] [Related]
17. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME).
Shindel AW
J Sex Med; 2009 Jul; 6(7):1794-808; quiz 1793, 1809-10. PubMed ID: 19575771
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism.
Champion HC; Bivalacqua TJ; Takimoto E; Kass DA; Burnett AL
Proc Natl Acad Sci U S A; 2005 Feb; 102(5):1661-6. PubMed ID: 15668387
[TBL] [Abstract][Full Text] [Related]
19. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction.
Kang KK; Yu JY; Yoo M; Kwon JW
Int J Impot Res; 2005; 17(5):409-16. PubMed ID: 15920460
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells.
Vernet D; Magee T; Qian A; Nolazco G; Rajfer J; Gonzalez-Cadavid N
J Sex Med; 2006 Jan; 3(1):84-94; discussion 94-5. PubMed ID: 16409221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
